Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study sequenced and analyzed the goat skin transcriptome, revealing genes involved in signal transduction and cell communication that are differentially expressed during hair growth phases, providing insights for Cashmere goat breeding.

This study explored hair follicle gene expression in Inner Mongolia Cashmere goats and identified potential regulators of the transition between growth phases, including IL17RB and ZNF genes.

In this study, detailed examinations of alopecic lesions in two female Cronkhite-Canada syndrome patients suggested hair regrowth might occur without systemic corticosteroids if not required for gastrointestinal treatment, and hair loss may begin with anagen-telogen transition.

This case report describes a 16-year-old girl initially diagnosed with chronic telogen effluvium, later reassessed with Ludwig Stage 1 androgenetic alopecia, for which she began spironolactone treatment.

This study found that iron deficiency anemia is a key factor in the development of telogen effluvium, and higher 25-hydroxyvitamin D3 levels in TE patients may be linked to increased UV exposure.

This review discusses "follicular hypoglycania" as a potential pathology in hair growth disorders and reports that proteoglycan replacement therapy may improve hair loss treatments, though it presents no new clinical trial results.

This article discusses the potential association between stress, poor sleep, and telogen effluvium during the COVID-19 pandemic, highlighting the possible role of substance P, but reports no new clinical results.

This study found that overexpressing the gene Thymosin β4 (Tβ4) can promote the growth and development of secondary hair follicle dermal papilla cells in cashmere goats, suggesting its potential as a target for increasing cashmere production.

This study found that a 12-week supplementation with MePL, a solution of miliacin encapsulated within polar lipids, significantly reduced hair density in the telogen phase and improved scalp dryness and hair brightness in women with telogen effluvium.

In this study, the TRICHOBIOLIGHT protocol showed effectiveness in treating androgenetic alopecia and telogen effluvium, with 82.5% of 103 patients experiencing excellent to good outcomes after mesotherapy and LED photobiostimulation on the scalp.

In this case report, a patient experienced hair loss after a surgical procedure but did not encounter the same issue following a later surgery with similar anesthesia.

This review discusses the causes and understanding of telogen effluvium, a form of hair loss following physiological stress, and provides no new clinical findings.

A liquid protein diet caused hair loss in a young woman.

This study concluded that Growth Factor Concentrate was more effective than Platelet-Rich Plasma in enhancing hair growth and patient satisfaction for individuals with androgenic alopecia and telogen effluvium, while maintaining similar safety.

The abstract does not provide any specific research findings or results, but rather serves as a promotional description for IP Innovative Publication Pvt Limited, highlighting their services and publication offerings in medical journals and related fields from Delhi, India.

This study observed that among male patients who experienced telogen effluvium after platelet-rich plasma treatment for androgenic alopecia, there were elevated levels of TNF-α, androgen receptors, and altered 5α-reductase gene expression, suggesting these factors as potential contributors to this unintended outcome.

This study found that Biofield Energy Healing Treatment on a herbal mixture increased hair growth and melanogenesis in mice compared to an untreated group.

This study found that claudins CLDN1 and CLDN3 are crucial for maintaining proper hair follicle structure in mice, and their dysregulation may lead to telogen hair loss.

This article discusses a severe case of telogen effluvium following brow ptosis repair and stresses the importance of recognizing and addressing stress-induced hair loss, without presenting new clinical findings.

In a depilated mouse model, this study found that blocking CXCL4 activity with an anti-CXCL4 monoclonal antibody promoted hair growth by inducing an earlier anagen phase, delaying hair follicle regression, and altering expression of genes and proteins related to hair growth and cell proliferation.

In this study, a Monte Carlo-generated synthetic cohort analysis found that higher simulated cannabis exposure was linked to increased self-assessed hair loss severity and reduced follicular density, suggesting potential connections worth exploring in further clinical research.

In this study, GV-350 treatment over three months improved iron status and reduced the impact of Telogen Effluvium on quality of life among 20 iron-deficient women, with no adverse events reported.

This review discusses various factors influencing hair growth, including alopecia and hirsutism, and highlights recent advancements in treatment approaches without reporting new clinical results.

This study found that TRH modulates specific keratins in human scalp tissue, suggesting its potential influence on hair growth and the need for further exploration of neuroendocrine controls in keratin expression.

The drinkable supplement increased hair growth and was safe for women with hair loss.

The authors concluded that chronic telogen effluvium in middle-aged women presents distinct clinical and histological features that differ from androgenetic alopecia and acute telogen effluvium.

This study found that the washing method can help differentiate chronic telogen effluvium from mild female pattern hair loss, potentially reducing the need for biopsies.

In this study, researchers used a rodent model to uncover key changes in how hair fibers detach, suggesting that the exogen phase should be subdivided based on club fiber status.

This study found that specific polymorphisms in the VDR gene, Taq1, and Cdx1, were significantly associated with increased risk of chronic telogen effluvium in women.

In this study, the novel isoprenylcysteine analog SIG-1451 was shown to inhibit pro-inflammatory cytokine release in various cell-based assays relevant to allergic dermatitis, acting on targets such as IL-4 and IL-6 with potential anti-inflammatory benefits.